KRAS and lung cancer: Other driver biomarkers in lung cancer (point mutations, rearrangements or amplifications in specific genes including KRAS, NRAS, HER2, BRAF, ALK, RET, and ROS1) have also been proposed and some of them might provide additional information for clinical decision-making.